top of page
LATEST NEWS
Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
4 hours ago3 min read


Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Every approval and rejection Gene Tech Times has covered, and the pattern they show.
17 hours ago3 min read


CRISPR for Cholesterol and Triglycerides: Everything We've Covered
Gene editing is moving from rare disease to high cholesterol and high triglycerides. Every Gene Tech Times story on PCSK9 and ANGPTL3 editing, and the argument it starts.
17 hours ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


FDA Grants Priority Review to uniQure's Huntington's Gene Therapy AMT-130, Decision Due May 2027
The FDA accepted uniQure's BLA for AMT-130 under accelerated approval with Priority Review and a May 1, 2027 decision date. It could become the first gene therapy for Huntington's disease.
Nov 7


One CRISPR Dose, 87% Fewer Attacks: Inside Intellia's Phase 3 Win for Hereditary Angioedema
Intellia's one-time CRISPR therapy lonvo-z cut hereditary angioedema attacks by 87% in the Phase 3 HAELO trial. In its August update, the company set a U.S. launch target of early 2027. Here's how it works.
Aug 5


FDA Reverses Course on uniQure's Huntington's Gene Therapy
In June 2026 the FDA agreed that three-year data for uniQure's AMT-130 could support accelerated approval for Huntington's disease, reversing its late-2025 stance. Here's the science and the regulatory drama.
Jun 16


One Infusion, Lower Cholesterol: Early Data Back Lilly's Bet on Verve
Phase 1 data for VERVE-102, a one-time base-editing treatment that switches off PCSK9, showed LDL cholesterol cuts of up to 62% lasting up to 18 months. Here's what it means for heart disease.
May 24


A Gene Therapy for Dravet Syndrome Cuts Seizures and Supports Development
At ASGCT 2026, Encoded Therapeutics shared one-year data for ETX101, an AAV9 gene regulation therapy for Dravet syndrome that cut seizures by about 76% at the top dose. A pivotal study is now underway.
May 12
bottom of page


